Elixinol Global Limited, a manufacturer of hemp-derived CBD dietary supplements, food and wellness products, announced today the release of its financial results for the first half of 2018. Revenue for the half was up by approximately 119%, rising to AU$12.5 million. The company credits its rising revenue to an increase in products sold through its Colorado-based business, Elixinol. EBITDA for the half rose to AU$2.2 million. However, the EBITDA margin slightly declined from 19.9% to 17.2%. The lower EBITDA margin was primarily due to strong volume growth in products that carry a lower profit margin.